Dose Insider / Glossary / Food noise

Food noiseConstant thoughts about food, and what GLP-1 drugs do to them

Updated November 20, 2026 · 4 min read · Hayashi 2023 review; 2025 joint nutrition advisory; Blundell 2017, Friedrichsen 2021, Gibbons 2021, Heise 2023

Food noise is a popular name for persistent thoughts about food and preoccupation with it.

38.9%Oral semaglutide 14 mg, 12 weeks, less eaten in appetite tests
Less eaten in appetite testsSemaglutide against placebo, % less foodOral semaglutide 14 mg, 12 weeks38.9%Semaglutide 2.4 mg, 20 weeks35.0%Semaglutide 1 mg, 12 weeks24.0%Less eaten in appetite testsSemaglutide against placebo, % less foodOral semaglutide 14 mg, 12 weeks38.9%Semaglutide 2.4 mg, 20 weeks35.0%Semaglutide 1 mg, 12 weeks24.0%

Each trial measured a test lunch or a whole test day.

On this page

A 2023 review notes that it is a colloquial term, which spread as patients and clinicians reported less rumination and preoccupation about food on GLP-1 medicines such as semaglutide.1 A 2025 advisory from four medical societies uses the term for preoccupation with food and lists its reduction among the effects of these medicines.2

What researchers call it

Because food noise is not a clinical term, the 2023 review looks at it through an established research concept: food cue reactivity, the way people respond to food cues. Those cues can be external or internal. The authors propose a model they call CIRO, for Cue, Influencer, Reactivity and Outcome. It sets out the factors that decide how strongly a person reacts to a food cue, and how that reaction shapes eating in the short and the long term. They offer it as a framework for future studies of food noise.1

What the appetite trials measured

No trial has used food noise as its outcome, but appetite trials measure the pieces of it. People eat at will at a test meal or over a test day, and fill in questionnaires on hunger, cravings and control over eating:

The advisory sums up the wider research the same way: less preoccupation with food, less emotional eating, less eating in response to outside triggers, and fewer binge episodes. Its authors add from their own clinics that many patients become less interested in food.2

What changes besides the amount

The trials also saw shifts in what people preferred. In the 12-week trial of semaglutide 1 mg, people on the drug showed a lower preference for high-fat foods.3 In the trial of oral semaglutide, a fat-rich breakfast left people fuller and less hungry on the drug than on placebo, while a standard breakfast showed no reliable difference.5 Outside the lab, a food-record study of 69 people who had used a GLP-1 for at least a month found an average intake of 1,748 kcal a day, 1,700 for women and 1,933 for men. Added sugars averaged 11.5 g a day, far under the 50 g reference.7

None of these studies asked people about food noise by name or measured it directly. What they show is the set of changes that people describe with this popular term: less hunger, fewer cravings, smaller meals and more control.

The flip side

The advisory also names the cost. When food stops being interesting, it becomes easy to eat too little or too narrowly. A large, rapid drop in intake can leave too few essential vitamins and minerals, especially below 1,200 kcal a day for women and 1,800 for men.2 Our page on what to eat on a GLP-1 covers how to keep meals complete when appetite is low.

Sources

  1. Hayashi D, Edwards C, Emond JA, et al. What is food noise? A conceptual model of food cue reactivity. Nutrients 2023;15:4809. doi:10.3390/nu15224809
  2. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. Obesity (Silver Spring) 2025;33:1475-1503. doi:10.1002/oby.24336
  3. Blundell J, Finlayson G, Axelsen M, Flint A, Gibbons C, Kvist T, Hjerpsted JB. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes Obes Metab 2017;19:1242-1251. doi:10.1111/dom.12932
  4. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab 2021;23:754-762. doi:10.1111/dom.14280
  5. Gibbons C, Blundell J, Tetens Hoff S, Dahl K, Bauer R, Baekdal T. Effects of oral semaglutide on energy intake, food preference, appetite, control of eating and body weight in subjects with type 2 diabetes. Diabetes Obes Metab 2021;23:581-588. doi:10.1111/dom.14255
  6. Heise T, DeVries JH, Urva S, et al. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes. Diabetes Care 2023;46:998-1004. doi:10.2337/dc22-1710
  7. Johnson B, Milstead M, Thomas O, McGlasson T, Green L, Kreider R, Jones R. Investigating nutrient intake during use of glucagon-like peptide-1 receptor agonist: a cross-sectional study. Front Nutr 2025;12:1566498. doi:10.3389/fnut.2025.1566498

Related analyses

Rate your food thoughts from 0 to 10 each day next to your dose, and watch the trend.

Open Dose Insider